Technology evaluation: Sch-58500, Canji.
Sch-58500 is a gene therapy utilizing the p53 gene and is under development by Canji and Schering-Plough for the potential treatment of various types of cancer. It is in phase II/III clinical trials in the US for stage III ovarian cancer [328228,328893], phase II clinical trials for hepatocellular and colorectal cancer metastatic to the liver [273331,324279], and phase I clinical trials for several other types of cancer [282801,284932,328228].
Institute for Antiviral Research, Utah State University, 5600 Main Hill, Logan, UT 84322, USA. honery@cc.usu.edu
D L
DL
Barnard
D000256:Adenoviridae / Q000235:genetics; D001709:Biotechnology; D005260:Female; D016158:Genes, p53; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D009154:Mutation; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D012449:Safety